You finally get the prescription you've been chasing for months.
A tiny pill. No needles. The promise of real weight loss.
You open the insurance portal to check the price…
and the screen just says: not covered.
Welcome to the GLP-1 squeeze of 2026.
When Novo Nordisk's Wegovy pill hit shelves in January, and Eli Lilly's Foundayo started shipping in April, the hope was simple.
No needles. Lower price. Wider access.
One out of two came true.
The needles are gone. The price? Basically identical to the shot.
The list price still sits between $1,000 and $1,350 a month.
Even after every discount, employers shell out roughly $569 to $664 per employee, per month.
Then multiply that by the flood of people who'd rather swallow a pill than stab themselves weekly.
👉 87% of employers expect the pill to spike demand.
👉 Only 9% think prices will drop.
👉 51% now call GLP-1s the number one driver of rising drug costs.
"Employers say the rise in pharmacy costs is unsustainable."
Mercer's latest data shows the pullback is already happening:
Even Blue Cross Blue Shield of Massachusetts ended Wegovy and Zepbound coverage heading into 2026.
Here's the uncomfortable part.
Employees love these drugs. 29% say they'd switch jobs to get GLP-1 coverage.
But employers see something else:
People start the drug. Pay thousands. Then quit. And the weight comes right back.
So the company eats the cost… and gets none of the long-term health payoff.
Workarounds are popping up everywhere:
More competition is coming. More approvals are coming. Prices will fall.
Just not this year.
The miracle pill arrived.
The miracle price did not.
And until it does, the cheapest GLP-1 might be the one your boss never lets you see.
That's all for now!
